What Projections Are Made for The Bleeding Disorders Treatment Market Size and Growth Rate?
The bleeding disorders treatment market has exhibited strong growth in recent years. From $16.95 billion in 2024, it is projected to grow to $18.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period is credited to increased patient awareness, access to healthcare, advancements in hemophilia therapies, and global market expansion. The market size is poised to display robust growth in the upcoming years, anticipated to reach $26.14 billion by 2029 at a CAGR of 9.0%. The growth during the forecast period can be attributed to the aging population, personalized medicine, patient advocacy and support, rise in disposable income, increased healthcare expenditure. Key trends in the forecast period include personalized treatment plans, expansion of telehealth services, advanced clotting factor therapies, RNA-based treatments, access to orphan drug designation.
Get your free sample of The Global Bleeding Disorders Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7843&type=smp
What Growth Drivers are Spurring the Bleeding Disorders Treatment Market Effortlessly?
The growth of the bleeding disorders treatment market is propelled by the rise in the number of diagnosed hemophilia patients. Hemophilia is an inherited bleeding disorder where the blood does not clot properly. The treatment entails replacement therapy, which replaces missing or insufficient blood clotting factors with human plasma concentrates or recombinant forms of clotting factors VIII or IX. For instance, as per the World Federation of Hemophilia (WFH), as of 2022, there were 257,146 identified patients with hemophilia worldwide, including 208,957 with Hemophilia A and 42,203 with Hemophilia B.Therefore, the increasing count of diagnosed hemophilia patients is steering the growth of the bleeding disorders treatment market.
What are the Significant Segments in the Bleeding Disorders Treatment Market?
1) By Treatment: Desmopressin (DDAVP), Hormone Replacement Therapy, Contraceptives, Anti-Fibrinolytic or Clot-Stabilizing Drugs, Fibrin Sealants, Drugs Applied To Cuts, Pipeline Analysis
2) By Disease Type: Hemophilia A, Hemophilia B, Von Willebrand disease, Liver disease, Other Disease Types
3) By End User: Hospitals, Clinics, Specialty Clinics, Research Institutes, Other End Users
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report
Who are the Key Players in the Bleeding Disorders Treatment Market?
Key players operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.
What Emerging Trends are Influencing the Bleeding Disorders Treatment Market?
Major players in the bleeding disorders treatment market are focusing on innovative technologies, such as single-dose treatment, to augment treatment effectiveness and improve the quality of life of patients by reducing the necessity for ongoing therapies. Single-dose treatment refers to a therapeutic strategy that offers a complete treatment in a single administration, aiming for enduring effects without the requirement for multiple doses. For example, in June 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology company, launched BioMarin’s ROCTAVIANTM (valoctocogene roxaparvovec-rvox). ROCTAVIAN is designed for adults with severe hemophilia A (defined as FVIII activity levels below 1 IU/dL) who do not have pre-existing antibodies to adeno-associated virus serotype 5 (AAV5).
Which Region Will Spearhead Growth in the Bleeding Disorders Treatment Market?
North America was the largest region in the bleeding disorders treatment market in 2024. However, Asia-Pacific is projected to be the fastest-growing region in the forecast period. The regions under study in the report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does the Bleeding Disorders Treatment Market Report 2025 Offer?
Bleeding Disorders Treatment refers to medical therapies and interventions used to manage and control conditions that perturb the blood’s capacity to clot properly. These treatments are designed to impede excessive bleeding, manage symptoms, and enhance the quality of life. The Bleeding Disorders Treatment Market research report from The Business Research Company presents global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7843
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has carved a reputation for offering comprehensive, data-rich research and insights. With 1,500,000 datasets, profound secondary research, and unique insights from industry leaders, you can acquire the information you need to stay ahead. Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to bolster informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
